- Trials with a EudraCT protocol (1)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
		
	   		
	   		    
                    
                   	
                   	    1 result(s) found for: 2022-001152-42.
                    
                
			
   			
		
		Displaying page 1 of 1.
	
	
| EudraCT Number: 2022-001152-42 | Sponsor Protocol Number: ShaperonC002 | Start Date*: 2022-09-05 | |||||||||||
| Sponsor Name:Shaperon, Inc. | |||||||||||||
| Full Title: A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepinĀ® Intravenous Infusion in COVID... | |||||||||||||
| Medical condition: COVID-19 Pneumonia Patients | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Completed) HR (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
 .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
 Query did not match any studies.
    	Query did not match any studies.
     
				
